Activist investor won’t push for board seats, but could still agitate from the sidelines if Pfizer’s stock continues to ...

The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.

Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

Dividend stocks have remained a focal point for investors, especially amid market volatility and the growing need for steady ...

Pfizer (NYSE:PFE – Get Free Report) had its price objective decreased by equities research analysts at Citigroup from $30.00 ...

Pfizer Inc. (NYSE:PFE – Get Free Report)’s share price traded down 0.6% during trading on Tuesday after Citigroup lowered their price target on the stock from $30.00 to $29.00. Citigroup currently has ...

In 2022, pharmaceutical giant Pfizer (NYSE: PFE) became the first healthcare company to generate $100 billion in annual sales ...

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from ...

In 2024, companies in the broader market that paid dividends returned around 35% of their net income and 45% of their free ...

Pfizer Inc (PFE) stock saw a decline, ending the day at $26.3 which represents a decrease of $-0.19 or -0.72% from the prior close of $26.49. The stock opened at $26.4 and touched a low of $26.22 ...